12:00 AM
 | 
Feb 15, 2010
 |  BC Week In Review  |  Company News  |  Deals

Artery Therapeutics, Roche deal

The companies will co-develop Artery's apolipoprotein A-1 (APOA1) peptide mimetics. The deal includes Artery's lead, AT5261, which...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >